Specifically, it activates the GIP, GLP-1, and glucagon receptors at the same time
Absence of medical history review
Your specific dosing path depends on baseline health markers, body weight, metabolic rate, and how your GLP-1 receptors respond to the medication
Summary measures and synthesis of results The principal summary outcome was the relative risk (RR) of several GI adverse events in people with overweight or obesity receiving treatment with GLP-1 RA, including nausea, vomiting, diarrhea, constipation, abdominal distension, upper abdominal pain, abdominal pain, abdominal discomfort, gastroesophageal reflux disease, (GERD), eructation, flatulence, decreased appetite, cholelithiasis, gallstone-related, cholecystitis, acute cholecystitis, acute pancreatitis, viral gastroenteritis, hard feces, and infrequent bowel movements